Results 291 to 300 of about 62,786 (347)

Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims There is limited evidence regarding whether obesity modifies the association between the use of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) and the risk of cardiovascular events. We assessed whether baseline body mass index (BMI) modifies the association between SGLT2i use and the risk of major adverse cardiovascular events (MACE)
Hwa Yeon Ko, Kyungyeon Jung, Yongtai Cho, Sungho Bea, Jae Hyun Bae, Young Min Cho, Sang Youl Rhee, Ju‐Young Shin   +7 more
wiley   +1 more source

Case report: Reversible Fanconi syndrome due to vitamin D deficiency in a patient with epilepsy harbouring a pathogenic variant in the SLC34A1 gene. [PDF]

Front Endocrinol (Lausanne)
Improda N, Rosanio FM, Annicchiarico Petruzzelli L, Ambrosio G, Malgieri G, Mandato C, Licenziati MR.   +6 more
europepmc   +1 more source

Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review. [PDF]

Cureus
Alsuwayh AF, Altawili M, Alhazmi MF, Alotaibi DFM, Rashed AO, Obaid Abdullah AH, Alkenani AAN, Almohammdi RAS, Alotaibi HFM, Mohamed Alsharif FEA.   +9 more
europepmc   +1 more source

Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus. [PDF]

Cardiovasc Diagn Ther
Wang K, Fan T, He F, Li H, Fang Y, Hu G, Wang X.   +6 more
europepmc   +1 more source

Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function. [PDF]

J Cardiovasc Imaging
Jeon K, Jang SY, Lee YB, Kim J, Kim D, Chang SA, Park SJ, Lee SC, Park SW, Lee MK, Kim EK, Hur KY.   +11 more
europepmc   +1 more source

Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review. [PDF]

Cureus
Khan HK, Ashfaq Z, Jamil H, Yaqoob H, Anthony N, Dilawar R, Ahmad B, Nabi S, Rania SA, Saleem F, Gerges M, Mikhael DM.   +11 more
europepmc   +1 more source

Plasma Potassium Negatively Correlates With Sodium Chloride Cotransporter Abundance and Phosphorylation in Urinary Extracellular Vesicles From Patients With Chronic Kidney Disease. [PDF]

Nephrology (Carlton)
Wu A, Wolley MJ, Vesey D, Terker AS, Welling PA, Fenton RA, Stowasser M.   +6 more
europepmc   +1 more source

Section 9: Pharmacologic Approaches to Glycemic Treatment. [PDF]

Clin Diabetes
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation

Diabetes, obesity and metabolism, 2021
To evaluate whether sodium‐glucose cotransporter‐2 (SGLT2) inhibition reduces cellular senescence in the kidney and to investigate the molecular pathways involved in the renoprotective effect.
Mi Na Kim, Joon Ho Moon, Y. Cho
semanticscholar   +1 more source